Kesmalea is creating a new generation of protein homeostasis modulators, with a unique chemistry platform technology and therapeutic paradigm. Our novel approach allows us to overcome the challenges of existing protein degradation and stabilisation technologies, opening the door to previously unavailable oral therapeutics in areas of high unmet medical need.

Protein homeostasis is the system of maintaining the equilibrium of proteins in the human body. This intricate system is in a constant state of change, with the body continuously synthesising and regulating proteins, whilst removing those which are no longer required (or have mutated) through controlled degradation. Small perturbations of the human body’s natural control mechanism that result in an excess or absence of certain proteins can drive the progression of disease. At Kesmalea, we’re aiming to counter this dysregulation with novel treatments which restore balance through effective protein degradation or stabilisation.

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Therapeutics

Kesmalea Therapeutics

Magdalena Jonikas

Roman Rothaermel

Mark Fox

Justin Bower

Habib Bouguenina

Kesmalea Therapeutics

Org chart

Similar companies